70817-26-4

Usage

Uses

Used in Pharmaceutical Industry:
(1-Phenyl-1H-pyrazol-4-yl)methanol is used as a key intermediate in the synthesis of pharmaceutical drugs due to its ability to be incorporated into the molecular structures of various bioactive compounds, enhancing their therapeutic potential.
Used in Chemical Research:
In the realm of chemical research, (1-Phenyl-1H-pyrazol-4-yl)methanol is utilized for its diverse reactivity, allowing scientists to explore new chemical pathways and reactions, contributing to the advancement of organic synthesis.
Used in Drug Development:
Owing to its demonstrated biological activities, such as anti-inflammatory and analgesic effects, (1-Phenyl-1H-pyrazol-4-yl)methanol is considered a potential candidate for the development of new drugs, particularly those aimed at treating conditions that benefit from these properties.
Used in Organic Synthesis:
(1-Phenyl-1H-pyrazol-4-yl)methanol's solubility in organic solvents and its crystalline nature make it a preferred compound in organic synthesis for the creation of a wide range of chemical products, from specialty chemicals to complex organic molecules.

InChI:InChI=1/C10H10N2O/c13-8-9-6-11-12(7-9)10-4-2-1-3-5-10/h1-7,13H,8H2

Upstream product

• 591-50-4 iodobenzene 
• 59-88-1 phenylhydrazine hydrochloride 
• 7188-96-7 1-Phenylpyrazol-4-carbonsaeure-methylester 
• 107-19-7 propargyl alcohol 
• 508191-77-3 3-phenylsydnone 
• 100-63-0 phenylhydrazine 
• 1126-00-7 1-phenylpyrazole 
• 885-94-9 ethyl 1-phenylpyrazole-4-carboxylate 
• 1134-50-5 4-carboxy-1-phenylpyrazole 
• 54605-72-0 1-phenyl-1H-pyrazole-4-carbaldehyde 

Downstream Products

• 1195983-01-7 (R)-3-(1-phenylcycloheptanecarbonyloxy)-1-(1-phenyl-1H-pyrazol-4-ylmethyl)-1-azoniabicyclo[2.2.2]octane chloride 
• 1195983-13-1 (R)-1-(1-phenyl-1H-pyrazol-4-ylmethyl)-3-(1-thiophen-2-ylcycloheptanecarbonyloxy)-1-azoniabicyclo[2.2.2]octane chloride 
• 54605-72-0 1-phenyl-1H-pyrazole-4-carbaldehyde 
• 35715-71-0 1-phenyl-4-pyrazolylmethyl chloride 
• 35715-77-6 (1-phenyl-1H-pyrazol-4-yl)-acetic acid 
• 51412-23-8 (1-phenyl-1H-pyrazol-4-yl)-acetonitrile 
• 101893-32-7 1,1'-phenyl-4,4'-dipyrazolylmethane 

Relevant academic research and scientific papers

NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF

The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an act

Anti-inflammatory and antinociceptive activity profile of a new lead compound – LQFM219

LQFM219 is a molecule designed from celecoxibe (COX-2 inhibitor) and darbufelone (inhibitor of COX-2 and 5-LOX) lead compounds through a molecular hybridisation strategy. Therefore, this work aimed to investigate the antinociceptive and anti-inflammatory activities of this new hybrid compound. The acute oral systemic toxicity of LQFM219 was evaluated via the neutral red uptake assay. Acetic acid-induced abdominal writhing and CFA-induced mechanical hyperalgesia were performed to evaluate the antinociceptive activity, and the anti-oedematogenic activity was studied by CFA-induced paw oedema and croton oil-induced ear oedema. Moreover, the acute anti-inflammatory activity was determined by carrageenan-induced pleurisy. In addition, cell migration, myeloperoxidase enzyme activity, and TNF-α and IL-1β levels were determined in pleural exudate. Moreover, a redox assay was conducted using electroanalytical and DPPH methods. The results demonstrated that LQFM219 was classified as GHS category 4, and it showed better free radical scavenger activity compared to BHT. Besides, LQFM219 decreased the number of writhings induced by acetic acid and the response to the mechanical stimulus in the CFA-induced mechanical hyperalgesia test. Furthermore, LQFM219 reduced oedema formation, cell migration, and IL-1β and TNF-α levels in the pleural cavity and inhibited myeloperoxidase enzyme activity. Thus, our study provides that the new pyrazole derivative, LQFM219, demonstrated low toxicity, antinociceptive and anti-inflammatory potential in vitro and in vivo.

Solvent-free and montmorillonite K10-catalyzed domino reactions for the synthesis of pyrazoles with alkynylester as a dual synthon

A highly regioselective, solvent-free and montmorillonite K10 clay-catalyzed domino process with an unprecedented ring-closing C-C bond-formation reaction is described for the synthesis of a new class of 1,3,4-trisubstituted and 1,4-disubstituted pyrazole

Pyridazinone compounds and use thereof (by machine translation)

The invention discloses a pyridazinone compounds, structure such as formula I shown: In the type of each substituent is as defined in the specification. The compounds of this invention have broad-spectrum antibacterial, insecticidal or acaricidal activity, the cucumber downy mildew, wheat powdery mildew, corn rust, rice blast, cucumber anthracnose and has excellent control effect. (by machine translation)

TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Cu-catalysed pyrazole synthesis in continuous flow

The synthesis of 1,4-disubstituted pyrazoles via the cycloaddition reaction of sydnones and terminal alkynes has been achieved employing silica-supported copper catalysts. Furthermore, this methodology has been successfully implemented in continuous flow

NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARγ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure (I) wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.